Effect of Testosterone Replacement on Anemia and Quality of Life amongst Patients on Maintenance Hemodialysis

Muhammad Haseeb Lodhi; Abdul Rehman Arshad; Qurat Ul Ain Azam; Malik Nadeem Azam Khan; Hummain Baber; Muhammad Umair Yasin

doi:10.51253/pafmj.v76iSUPPL-1.12984

Authors

Muhammad Haseeb Lodhi Department of Medicine, Pak Emirates Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Abdul Rehman Arshad Department of Medicine, Pak Emirates Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Qurat Ul Ain Azam Department of Medicine, Pak Emirates Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Malik Nadeem Azam Khan Department of Medicine, Pak Emirates Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Hummain Baber Department of Medicine, Pak Emirates Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Muhammad Umair Yasin Department of Medicine, Pak Emirates Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76iSUPPL-1.12984

Keywords:

Anemia, hemodialysis, Replacement, renal failure, Testosterone, quality

Abstract

Objective: To study the effect of Testosterone replacement therapy in improving the level of anemia and quality of life in males undergoing hemodialysis due to chronic renal failure (CRF).

Study Design: Randomized controlled trial (ANZCTR Trial ID ACTRN12624001137583).

Place and Duration of Study: Department of Medicine, Pak Emirates Military Hospital, Rawalpindi, Pakistan from Jan 2024 to Jun 2024.

Methodology: 160 patients were randomized into two groups, one to receive Testosterone supplementation therapy (Group A) (n=80) and one to receive placebo (Group B) (n=80). Primary variables studied were improvement in Aging Males Symptoms (AMS) scores and Hb levels. Secondary variables were changes in Testosterone levels (free and total serum levels).

Results: 160 patients were randomized into two groups, one to receive Testosterone supplementation therapy (Group A) (n=80) and one to receive placebo (Group B) (n=80). Mean hemoglobin levels between both groups were 8.38±1.12 versus 8.34±1.12 g/dl before therapy (p=0.834), 8.13±1.12 versus 8.10±1.16 g/dl at 3 months of therapy (p=0.891) and 8.10±1.10 versus 8.09±1.17 g/dl at 6 months of therapy (p=0.945). Median (IQR) values for total AMS scores between both groups were 36.00 (3.00) versus 36.00 (2.00) before therapy (p=0.954), 34.00 (2.00) versus 36.00 (4.00) at 3 months of therapy (p<0.001) and 31.00 (3.00) versus 36.00 (4.00) at 6 months of therapy (p<0.001).

Conclusion: We conclude that phycological and somato-vegetative variables in patients were considerably improved with no improvement in sexual dysfunction and levels of hemoglobin in these patients.

Downloads

Download data is not yet available.

References

Wrzosek M, Woźniak J, Włodarek D. The causes of adverse changes of testosterone levels in men. Exp Rev Endocrinol Metabol 2020; 15(5): 355-362.

https://doi.org/10.1080/17446651.2020.1813020

2. Barone B, Napolitano L, Abate M, Cirillo L, Reccia P, Passaro F, et al. The role of testosterone in the elderly: what do we know? Int J Molecul Sci 2022; 23(7): 3535.

https://doi.org/10.3390/ijms23073535

3. Zhang D, Wei Y, Huang Q, Chen Y, Zeng K, Yang W, et al. Important hormones regulating lipid metabolism. Molecules 2022; 27(20): 7052.

https://doi.org/10.3390/molecules27207052

4. Gencer B, Bonomi M, Adorni MP, Sirtori CR, Mach F, Ruscica M et al. Cardiovascular risk and testosterone–from subclinical atherosclerosis to lipoprotein function to heart failure. Rev Endocrine Metabolic Dis 2021; 22: 257-274.

https://doi.org/10.1007/s11154-021-09628-2

5. Lombardo G, Mondelli V, Dazzan P, Pariante CM. Sex hormones and immune system: A possible interplay in affective disorders? A systematic review. J Affective Dis 2021; 290: 1-14.

https://doi.org/10.1016/j.jad.2021.04.035

6. Romejko K, Rymarz A, Sadownik H, Niemczyk S. Testosterone deficiency as one of the major endocrine disorders in chronic kidney disease. Nutrients 2022; 14(16): 3438.

https://doi.org/10.3390/nu14163438

7. Van der Burgh AC, Khan SR, Neggers SJ, Hoorn EJ, Chaker L. The role of serum testosterone and dehydroepiandrosterone sulfate in kidney function and clinical outcomes in chronic kidney disease: a systematic review and meta-analysis. Endocrine Connect 2022; 11(6): 61.

https://doi.org/10.1530/EC-22-0061

8. Imtiaz S, Alam A. Epidemiology and demography of Chronic Kidney Disease in Pakistan-A review of Pakistani literature. Pak J Kidney Dis 2023; 7(1): 2-7.

https://doi.org/10.53778/pjkd71209

9. Bhasin S, Seidman S, Travison TG, Pencina KM, Lincoff AM, Nissen SE, et al. Depressive Syndromes in Men With Hypogonadism in the TRAVERSE Trial: Response to Testosterone-Replacement Therapy. J Clin Endocrinol Metabol 2024; 109(7): 1814-1826.

https://doi.org/10.1210/clinem/dgae026

10. Moore C, Huebler D, Zimmermann T, Heinemann LA, Saad F. The Aging Males’ Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol 2004; 46(1): 80-87.

https://doi.org/10.1016/j.eururo.2004.01.009

11. Inoue Y, Nakamura K, Kuwahara Y, Lu Y, Masuda N, Horie S, et al. Efficacy of testosterone treatment in hemodialysis patients as assessed by aging males’ symptoms scores: a pilot study. Am J Men Health 2018; 12(5): 1541-1547.

https://doi.org/10.1177/1557988318772734

12. Luyckx VA, Cherney DZ, Bello AK. Preventing CKD in developed countries. Kidney Int Rep 2020; 5(3): 263-277.

https://doi.org/10.1016/j.ekir.2019.12.003

13. MacRae C, Mercer SW, Guthrie B, Henderson D. Comorbidity in chronic kidney disease: a large cross-sectional study of prevalence in Scottish primary care. Br J Gen Pract 2021; 71(704): e243-e9. https://doi.org/10.3399/bjgp20X714125

14. Katsumi A, Abe A, Tamura S, Matsushita T. Anemia in older adults as a geriatric syndrome: A review. Geriatr Gerontol Int 2021; 21(7): 549-54. https://doi.org/10.1111/ggi.14183

15. Yeo JK, Koo HS, Yu J, Park MG. Effects of testosterone treatment on quality of life in patients with chronic kidney disease. Am J Men Health 2020; 14(3): 1557988320917258.

https://doi.org/10.1177/1557988320917258

16. Carrero JJ, Bárány P, Yilmaz MI, Qureshi AR, Sonmez A, Heimbürger O, et al. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease. Nephrol Dialysis Transplant 2012; 27(2): 709-715.

https://doi.org/10.1093/ndt/gfr288

17. McCullough PA. Anemia of cardiorenal syndrome. Kidney Int Supp 2021; 11(1): 35-45.

https://doi.org/10.1016/j.kisu.2020.12.001

18. Salgado Filho N, Lages JS, Brito DJdA, Santos EJF, Dos Santos AM, de Souza FL, et al. Variability in hemoglobin levels and the factors associated with mortality in hemodialysis patients: a 78-month follow-up study. Int J Environment Res Public Health 2021; 18(3): 1078. https://doi.org/10.3390/ijerph18031078

19. Zhao JV, Schooling CM. The role of testosterone in chronic kidney disease and kidney function in men and women: a bi-directional Mendelian randomization study in the UK Biobank. BMC Med 2020; 18: 1-10.

https://doi.org/10.1186/s12916-020-01594-x